Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Weiss GJ, Beck J, Braun DP, Bornemann-Kolatzki K, Barilla H, Cubello R, Quan W Jr, Sangal A, Khemka V, Waypa J, Mitchell WM, Urnovitz H, Schütz E.

Clin Cancer Res. 2017 Sep 1;23(17):5074-5081. doi: 10.1158/1078-0432.CCR-17-0231. Epub 2017 Mar 20.

PMID:
28320758
2.

Retrospective analysis of pharmacist interventions in an ambulatory palliative care practice.

Ma JD, Tran V, Chan C, Mitchell WM, Atayee RS.

J Oncol Pharm Pract. 2016 Dec;22(6):757-765. Epub 2015 Oct 1.

PMID:
26428283
3.

Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).

Mitchell WM.

Expert Rev Clin Pharmacol. 2016 Jun;9(6):755-70. doi: 10.1586/17512433.2016.1172960. Review.

4.

The quest for effective Ebola treatment: Ebola VP35 is an evidence-based target for dsRNA drugs.

Mitchell WM, Carter WA.

Emerg Microbes Infect. 2014 Oct;3(10):e77. doi: 10.1038/emi.2014.77. Epub 2014 Oct 29. No abstract available.

5.

Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer.

Schütz E, Akbari MR, Beck J, Urnovitz H, Zhang WW, Bornemann-Kolatzki K, Mitchell WM, Nam RK, Narod SA.

Clin Chem. 2015 Jan;61(1):239-48. doi: 10.1373/clinchem.2014.226571. Epub 2014 Oct 27.

6.

Protection from pulmonary tissue damage associated with infection of cynomolgus macaques by highly pathogenic avian influenza virus (H5N1) by low dose natural human IFN-α administered to the buccal mucosa.

Strayer DR, Carter WA, Stouch BC, Stittelaar KJ, Thoolen RJ, Osterhaus AD, Mitchell WM.

Antiviral Res. 2014 Oct;110:175-80. doi: 10.1016/j.antiviral.2014.07.010. Epub 2014 Aug 9.

PMID:
25111905
7.

Palliative radiation before hospice: the long and the short of it.

Yeung HN, Mitchell WM, Roeland EJ, Xu B, Mell LK, Le QT, Murphy JD.

J Pain Symptom Manage. 2014 Dec;48(6):1070-9. doi: 10.1016/j.jpainsymman.2014.04.004. Epub 2014 May 10.

8.

Discordant biological and toxicological species responses to TLR3 activation.

Mitchell WM, Nicodemus CF, Carter WA, Horvath JC, Strayer DR.

Am J Pathol. 2014 Apr;184(4):1062-1072. doi: 10.1016/j.ajpath.2013.12.006. Epub 2014 Jan 30.

PMID:
24486326
9.

Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment.

Liu Q, Ma J, Strayer DR, Mitchell WM, Carter WA, Ma W, Richt JA.

Expert Rev Anti Infect Ther. 2014 Feb;12(2):165-9. doi: 10.1586/14787210.2014.870885. Epub 2013 Dec 18.

PMID:
24350808
10.

A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.

Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ, Lapp CW, Peterson DL; Chronic Fatigue Syndrome AMP-516 Study Group, Mitchell WM.

PLoS One. 2012;7(3):e31334. doi: 10.1371/journal.pone.0031334. Epub 2012 Mar 14.

11.

Serum DNA motifs predict disease and clinical status in multiple sclerosis.

Beck J, Urnovitz HB, Saresella M, Caputo D, Clerici M, Mitchell WM, Schütz E.

J Mol Diagn. 2010 May;12(3):312-9. doi: 10.2353/jmoldx.2010.090170. Epub 2010 Mar 12.

12.

Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls.

Beck J, Urnovitz HB, Mitchell WM, Schütz E.

Mol Cancer Res. 2010 Mar;8(3):335-42. doi: 10.1158/1541-7786.MCR-09-0314. Epub 2010 Mar 9.

13.

Qualitative and quantitative detection of Chlamydophila pneumoniae DNA in cerebrospinal fluid from multiple sclerosis patients and controls.

Tang YW, Sriram S, Li H, Yao SY, Meng S, Mitchell WM, Stratton CW.

PLoS One. 2009;4(4):e5200. doi: 10.1371/journal.pone.0005200. Epub 2009 Apr 9.

14.

The role of palliative medicine in cancer patient care.

Mitchell WM, von Gunten CF.

Cancer Treat Res. 2008;140:159-71. No abstract available.

PMID:
18283775
15.

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.

Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, Odagiri T, Tashiro M, Takahashi H, Sawa H, Mitchell WM, Strayer DR, Carter WA, Chiba J, Kurata T, Sata T, Hasegawa H.

J Infect Dis. 2007 Nov 1;196(9):1313-20. Epub 2007 Oct 5.

PMID:
17922395
16.
17.

18th International Conference on Antiviral Research.

Mitchell WM.

Expert Opin Pharmacother. 2005 Aug;6(10):1765-8.

PMID:
16086663
18.

Chlamydia pneumoniae and acute coronary syndrome.

Mitchell WM, Stratton CW.

N Engl J Med. 2005 Aug 4;353(5):525-8; author reply 525-8. No abstract available.

PMID:
16080250
19.

Culture and immunohistochemical evidence of Chlamydia pneumoniae infection in ulcerative pyoderma gangrenosum.

Sams HH, Mitchell WM, Stratton CW, King LE Jr.

J Am Acad Dermatol. 2003 Jun;48(6):966-9.

PMID:
12789196
20.

Chlamydia pneumoniae and chronic skin wounds: a focused review.

King LE Jr, Stratton CW, Mitchell WM.

J Investig Dermatol Symp Proc. 2001 Dec;6(3):233-7. Review.

21.

Diabetic foot ulcers and Chlamydia pneumoniae: innocent bystander or opportunistic pathogen?

King LE Jr, Bushman T, Stratton CW, Mitchell WM.

Arch Dermatol. 2001 May;137(5):671-2. No abstract available.

PMID:
11346358
22.

CSF oligoclonal bands in MS include antibodies against Chlamydophila antigens.

Yao SY, Stratton CW, Mitchell WM, Sriram S.

Neurology. 2001 May 8;56(9):1168-76.

PMID:
11342681
23.

Regulation by IFN-beta of inducible nitric oxide synthase and interleukin-12/p40 in murine macrophages cultured in the presence of Chlamydia pneumoniae antigens.

Yao SY, Ljunggren-Rose A, Stratton CW, Mitchell WM, Sriram S.

J Interferon Cytokine Res. 2001 Mar;21(3):137-46.

PMID:
11331036
24.

Pyoderma gangrenosum and Chlamydia pneumoniae infection in a diabetic man: pathogenic role or coincidence?

Vannucci SA, Mitchell WM, Stratton CW, King LE Jr.

J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):295-7.

PMID:
10642692
25.

Does Chlamydia pneumoniae play a role in the pathogenesis of multiple sclerosis?

Stratton CW, Mitchell WM, Sriram S.

J Med Microbiol. 2000 Jan;49(1):1-3. No abstract available.

PMID:
10628821
26.

Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis.

Sriram S, Stratton CW, Yao S, Tharp A, Ding L, Bannan JD, Mitchell WM.

Ann Neurol. 1999 Jul;46(1):6-14.

PMID:
10401775
27.

Chromosomal proviral sequences of human immunodeficiency virus in multiple thymic cell types in a patient with acquired immunodeficiency syndrome and massive thymic hyperplasia.

Fisher RG, Wilson GJ, Johnson JE, Scott MA, Mitchell WM.

Pediatr Infect Dis J. 1998 Nov;17(11):1050-2. No abstract available.

PMID:
9849994
28.
30.

Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.

Robinson WE Jr, Cordeiro M, Abdel-Malek S, Jia Q, Chow SA, Reinecke MG, Mitchell WM.

Mol Pharmacol. 1996 Oct;50(4):846-55.

PMID:
8863829
31.

Local upregulation of corticotropin-releasing hormone and interleukin-1 receptors in rats with painful hindlimb inflammation.

Mousa SA, Schäfer M, Mitchell WM, Hassan AH, Stein C.

Eur J Pharmacol. 1996 Sep 12;311(2-3):221-31.

PMID:
8891603
32.

Functional studies of bispecific antibodies directed against HIV-1 and the Fc gamma I receptor type I.

Gorny MK, Keler T, Burda S, Williams C, Gabriel JL, Mitchell WM, Deo YM, Zolla-Pazner S.

Antibiot Chemother (1971). 1996;48:173-83. No abstract available.

PMID:
8726522
33.

Induction of mucosal anti-HIV antibodies by facilitated transfection of airway epithelium with lipospermine/DNA complexes.

Mitchell WM, Rosenbloom ST, Gabriel J.

Immunotechnology. 1995 Dec;1(3-4):211-9.

PMID:
9373349
34.

Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques.

Mitchell WM, Torres J, Johnson PR, Hirsch V, Yilma T, Gardner MB, Robinson WE Jr.

AIDS. 1995 Jan;9(1):27-34.

PMID:
7893438
36.

In vivo binding of [125I]RTI-55 to dopamine transporters: pharmacology and regional distribution with autoradiography.

Cline EJ, Scheffel U, Boja JW, Mitchell WM, Carroll FI, Abraham P, Lewin AH, Kuhar MJ.

Synapse. 1992 Sep;12(1):37-46.

PMID:
1411962
37.

High-affinity binding of [125I]RTI-55 to dopamine and serotonin transporters in rat brain.

Boja JW, Mitchell WM, Patel A, Kopajtic TA, Carroll FI, Lewin AH, Abraham P, Kuhar MJ.

Synapse. 1992 Sep;12(1):27-36.

PMID:
1411961
38.
39.

Withdrawal of repeated cocaine decreases autoradiographic [3H]mazindol-labelling of dopamine transporter in rat nucleus accumbens.

Sharpe LG, Pilotte NS, Mitchell WM, De Souza EB.

Eur J Pharmacol. 1991 Oct 2;203(1):141-4.

PMID:
1797552
40.

Chronic cocaine administration and withdrawal of cocaine modify neurotensin binding in rat brain.

Pilotte NS, Mitchell WM, Sharpe LG, De Souza EB, Dax EM.

Synapse. 1991 Oct;9(2):111-20.

PMID:
1821482
41.

Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Robinson WE Jr, Gorny MK, Xu JY, Mitchell WM, Zolla-Pazner S.

J Virol. 1991 Aug;65(8):4169-76.

42.
43.

Chronic cocaine administration and withdrawal from cocaine modify central neurotensin receptors in rats.

Pilotte NS, Mitchell WM, Sharpe LG, De Souza E, Dax EM.

NIDA Res Monogr. 1990;105:541-2. No abstract available.

PMID:
1652092
44.

Interleukin-1 receptors in mouse brain: characterization and neuronal localization.

Takao T, Tracey DE, Mitchell WM, De Souza EB.

Endocrinology. 1990 Dec;127(6):3070-8.

PMID:
2147409
45.
46.

Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain.

Appel NM, Mitchell WM, Garlick RK, Glennon RA, Teitler M, De Souza EB.

J Pharmacol Exp Ther. 1990 Nov;255(2):843-57.

PMID:
2243353
47.

Identification of interleukin-1 receptors in mouse testis.

Takao T, Mitchell WM, Tracey DE, De Souza EB.

Endocrinology. 1990 Jul;127(1):251-8.

PMID:
2141815
48.

Effective inactivation of human immunodeficiency virus with chlorhexidine antiseptics containing detergents and alcohol.

Montefiori DC, Robinson WE Jr, Modliszewski A, Mitchell WM.

J Hosp Infect. 1990 Apr;15(3):279-82.

PMID:
1971635
49.

Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors.

Robinson WE Jr, Montefiori DC, Mitchell WM.

Virology. 1990 Apr;175(2):600-4.

PMID:
2327077
50.

Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.

Robinson WE Jr, Kawamura T, Gorny MK, Lake D, Xu JY, Matsumoto Y, Sugano T, Masuho Y, Mitchell WM, Hersh E, et al.

Proc Natl Acad Sci U S A. 1990 Apr;87(8):3185-9.

Supplemental Content

Loading ...
Support Center